531 results match your criteria: "Saint-Luc University Hospital[Affiliation]"
Epileptic Disord
November 2024
Clinical Neuroscience, UCL GOS Institute of Child Health and Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Objective: To employ the neonatal seizure framework developed by the International League Against Epilepsy (ILAE) Neonatal Task force to assess its usefulness in determining the etiology of neonatal seizures.
Methods: The members of the ILAE Neonatal Task Force evaluated 157 seizures from 146 neonates to determine internal validity and associations between semiology and a specific etiology.
Results: Provoked neonatal electrographic and electroclinical seizures were due to multiple etiologies.
Epilepsia
November 2024
Department of Pediatrics, Division of Pediatric Neurology, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
Objective: Few studies have evaluated the efficacy of antiseizure medications (ASMs) according to the etiology of neonatal acute provoked seizures. We aimed to investigate the response to ASMs in term/near term neonates with acute arterial ischemic stroke (AIS), as well as the type of seizure at presentation and the monitoring approach.
Methods: We retrospectively evaluated neonates from 15 European level IV neonatal intensive care units who presented with seizures due to AIS and were monitored by continuous electroencephalography (cEEG) and/or amplitude-integrated EEG (aEEG) in whom actual recordings, timing, doses, and response to ASMs were available for review.
Pediatr Res
October 2024
Division of Neonatology, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium.
Ann Intensive Care
October 2024
Department of Intensive Care Medicine, Mons-Hainaut Regional Hospital, Mons, Belgium.
Background: Convalescent plasma (CP) reduced the mortality in COVID-19 induced ARDS (C-ARDS) patients treated in the CONFIDENT trial. As patients are immunologically heterogeneous, we hypothesized that clusters may differ in their treatment responses to CP.
Methods: We measured 20 cytokines, chemokines and cell adhesion markers using a multiplex technique at the time of inclusion in the CONFIDENT trial in patients of centers having accepted to participate in this secondary study.
Ther Adv Hematol
September 2024
Goethe University, University Hospital Frankfurt, Department of Paediatrics and Adolescent Medicine, Frankfurt, Germany.
Alzheimers Dement
October 2024
Louvain Aging Brain Lab, Institute of Neuroscience, UCLouvain, Brussels, Belgium.
Pediatr Res
September 2024
Division of Pediatric Neurology, Department of Pediatrics, Saint-Luc University Hospital, and Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium.
J Orthop Case Rep
August 2024
Department of Orthopaedic and Trauma Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Pediatr Res
September 2024
Division of Pediatric Neurology, Department of Pediatrics, Saint-Luc University Hospital, and Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium.
Diagn Interv Imaging
November 2024
Centre Hospitalier de l'Université de Montréal Research Center (CRCHUM), Montreal, QC, H2 × 0A9, Canada; Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montreal, Montreal, QC, H3T 1J4, Canada. Electronic address:
Purpose: The purpose of this study was to evaluate the safety and efficacy of intralesional injection of chitosan hydrogel (CH) combined with sodium tetradecyl sulfate (STS) to sclerose and embolize venous malformations (VMs) by comparison with 3% STS foam and placebo in a mouse model.
Materials And Methods: Subcutaneous VMs were created by injecting HUVEC_TIE2-L914F cells, mixed with matrigel, into the back of athymic mice (Day [D] 0). After VM-like lesions were established at D10, 70 lesions were randomly assigned to one of six treatment groups (untreated, saline, 3% STS-foam, CH, 1% STS-CH, 3% STS-CH).
Clin Neurophysiol
September 2024
Institute of Neuroscience, Catholic University of Louvain, 1200 Brussels, Belgium.
Objective: Parkinson's disease (PD) patients exhibit changes in mechanisms underlying movement preparation, particularly the suppression of corticospinal excitability - termed "preparatory suppression" - which is thought to facilitate movement execution in healthy individuals. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) being an attractive treatment for advanced PD, we aimed to study the potential contribution of this nucleus to PD-related changes in such corticospinal dynamics.
Methods: On two consecutive days, we applied single-pulse transcranial magnetic stimulation to the primary motor cortex of 20 advanced PD patients treated with bilateral STN-DBS (ON vs.
Res Pract Thromb Haemost
May 2024
Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium.
Acquired hemophilia A (AHA) is a rare autoimmune disease resulting from the development of autoantibodies directed against endogenous factor (F)VIII, leading to bleeding manifestations that can be life-threatening. The current standard hemostatic treatment involves the use of bypassing agents that circumvent FVIII (recombinant activated FVII, activated prothrombin complex concentrate, and recombinant porcine FVIII) that must be administered intravenously and possess a short half-life. These limitations and the risk of potentially fatal bleeding complications justify the early initiation of immunosuppressive treatment (IST) aimed at promptly eradicating the autoantibodies.
View Article and Find Full Text PDFOrphanet J Rare Dis
May 2024
Division of Plastic Surgery, Center for Vascular Anomalies, Saint-Luc University Hospital, VASCERN VASCA European Reference Centre, UCLouvain, Cliniques Universitaires St Luc, Avenue Hippocrate 10, Brussels, B-1200, Belgium.
Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the spectrum of lymphatic malformations (LMs) that share similar oncogenic mutations to cancer. We report the case of a young patient with highly symptomatic CLA who was initially treated with sirolimus, due to the frequent involvement of the PI3K-AKT-mTOR pathway in CLA pathogenesis.
View Article and Find Full Text PDFPlast Reconstr Surg
May 2024
Center for Vascular Anomalies, Saint-Luc University Hospital, UCLouvain, Brussels, Belgium; VASCERN VASCA European Reference Centre.
Background: To assess the impact of propranolol as the first-line treatment of infantile hemangioma (IH) on the need for surgery in the management of IH.
Methods: Retrospective study of 420 patients, with IH, referred to our multidisciplinary center between January 2005 and August 2014. Clinical data including sex, age at first consultation and at treatment initiation, location, size, number, aspect, and complication of IH, as well as the type of treatment were collected.
J Neurosci
June 2024
Institute for Information and Communication Technologies, Electronics and Applied Mathematics, UCLouvain, Louvain-la-Neuve 1348, Belgium
Essential tremor (ET), a movement disorder characterized by involuntary oscillations of the limbs during movement, remains to date not well understood. It has been recently suggested that the tremor originates from impaired delay compensation, affecting movement representation and online control. Here we tested this hypothesis directly with 24 ET patients (14 female; 10 male) and 28 neurologically intact (NI) human volunteers (17 female; 11 male) in an upper limb postural perturbation task.
View Article and Find Full Text PDFJ Thromb Haemost
July 2024
World Federation of Hemophilia, Montreal, Quebec, Canada.
A remarkable step forward in the treatment of hemophilia A has recently been achieved with the development of an Ultra-Long modified factor (F)VIII. Leveraging expertise gained with fusion to immunoglobulin Fc fragments, disconnecting FVIII from endogenous von Willebrand factor (via a D'-D3 fragment), and benefiting from the pharmacokinetic prolongation provided by the addition of hydrophilic polypeptides, efanesoctocog alfa opens a new era in the treatment of hemophilia A. The term Ultra-Long FVIII has been proposed to designate it and differentiate it from extended half-life FVIII.
View Article and Find Full Text PDFArch Dis Child Fetal Neonatal Ed
October 2024
Department of Neonatology, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.
J Cancer Policy
June 2024
International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.
Haemophilia
April 2024
Radcliffe Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Nuffield Orthopedic Centre, Oxford University, Oxford, UK.
Raising awareness and improving recognition, accurate classification, and enhanced access to new treatments represent current key challenges for carriers of haemophilia. Women and girls carrying genes for haemophilia often experience significant bleeding and/or low factor levels. The bleeding associated with female haemophilia is frequently overlooked, has a weak correlation with factor levels, and manifests differently than in males, with heavy menstrual bleeding being a predominant symptom.
View Article and Find Full Text PDFInternational comparisons of cancer surveillance measures may provide insight into inequalities in registration practices, etiological factors, and treatment strategies. This study aimed to compare incidence, survival, and mortality of cancer in children and young adolescents between Belgium and the Netherlands. All children (0-14 years) and young adolescents (15-17 years) diagnosed with cancer between 2004 and 2015 were selected from the population-based cancer registries of Belgium (N = 4739) and the Netherlands (N = 7322).
View Article and Find Full Text PDFAnesthesiology
April 2024
Department of Anaesthesiology and Postoperative Pain Service, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium.
Front Oncol
February 2024
Université Catholique de Louvain, Institute of Neuroscience, Cellular and Molecular Division, Brussels, Belgium.
Background: Glioblastoma is one of the most aggressive primary brain tumors, with a poor outcome despite multimodal treatment. Methylation of the promoter, which predicts the response to temozolomide, is a well-established prognostic marker for glioblastoma. However, a difference in survival can still be detected within the methylated group, with some patients exhibiting a shorter survival than others, emphasizing the need for additional predictive factors.
View Article and Find Full Text PDFHaemophilia
May 2024
Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Acta Haematol
September 2024
Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Introduction: Acquired von Willebrand syndrome (AvWS) is a rare entity with approximately 700 cases described in the literature. A number of etiologies are responsible for this condition, mainly lymphoproliferative, myeloproliferative syndromes and cardiac diseases. Management is aimed at preventing and treating bleeds, as well as treating the underlying pathology.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
March 2024
Department of Obstetrics, Saint-Luc University Hospital, Université Catholique de Louvain (UCL), 10, Avenue Hippocrate, B-1200 Bruxelles, Belgium. Electronic address: